Management of ulcerative colitis

Enzychem Lifesciences Announces Positive Results for Phase 2 U.S. Study of EC-18 in Chemoradiation-Induced Oral Mucositis

Retrieved on: 
Wednesday, October 20, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Breakthrough therapy, Clinical trial, AES, Pain, Caregiver, Pharynx, Mouth, Șaeș, Head, SAE, Twitter, Patient, Cisplatin, Toxicity, Incidence, KOSDAQ, Chemoradiotherapy, Mucositis, Eating, SOM, Safety, FDA, Management of ulcerative colitis, CEO, Dentistry, Homeostasis, Radiation, Malnutrition, Stage 2, Dehydration, Inflammation, Edwards Lifesciences, Key Stage 1, Hospital, Pharmaceutical industry

Enzychem Lifesciences (KOSDAQ: 183490) announced today positive Phase 2 results from a U.S. clinical trial of its lead candidate EC-18 in chemoradiation-induced oral mucositis (CRIOM).

Key Points: 
  • Enzychem Lifesciences (KOSDAQ: 183490) announced today positive Phase 2 results from a U.S. clinical trial of its lead candidate EC-18 in chemoradiation-induced oral mucositis (CRIOM).
  • EC-18, a novel, first-in-class, small molecule oral immunomodulator, reduced the duration and incidence of severe oral mucositis in patients with head and neck cancer undergoing concurrent chemoradiation therapy.
  • Patients with the most severe form of oral mucositis often have to discontinue or modify their cancer treatment.
  • "We are delighted to announce these positive results from our Phase 2 U.S. study, which confirm that EC-18 is safe and well-tolerated, said Ki-Young Sohn, CEO & Chairman, Enzychem Lifesciences.

European Medicines Agency Validates Bristol Myers Squibb’s Application for Zeposia (ozanimod) for the Treatment of Ulcerative Colitis

Retrieved on: 
Monday, December 28, 2020
Health, FDA, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Clinical medicine, Immunology, Autoimmune diseases, Diarrhea, Monoclonal antibodies, Abdominal pain, Colitis, Ulcerative colitis, Ozanimod, Management of ulcerative colitis, Bristol Myers Squibb, True North, Ulcerative Colitis, Zeposia (ozanimod), Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) today announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for Zeposia (ozanimod) for the treatment of adults with moderately to severely active ulcerative colitis (UC).

Key Points: 
  • Bristol Myers Squibb (NYSE:BMY) today announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for Zeposia (ozanimod) for the treatment of adults with moderately to severely active ulcerative colitis (UC).
  • For the maintenance phase, 457 patients were re-randomized to maintenance treatment with either Zeposia (n=230) or placebo (n=227).
  • Bristol Myers Squibb is continuing to evaluate Zeposia in an open-label extension trial, which is ongoing and designed to assess the longer-term profile of Zeposia for the treatment of moderately to severely active ulcerative colitis.
  • Zeposia is not approved for the treatment of ulcerative colitis in any country.

European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Ulcerative Colitis

Retrieved on: 
Monday, November 2, 2020
Health, Hospitals, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medical specialties, Clinical medicine, Medicine, Autoimmune diseases, Diarrhea, Filgotinib, Colitis, Ulcerative colitis, Management of ulcerative colitis, Ulcer

View the full release here: https://www.businesswire.com/news/home/20201102005941/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20201102005941/en/
    Ulcerative colitis is a long term, chronic condition which affects more than 2 million people in the European Union alone.
  • The SELECTION trial results were presented at the virtual United European Gastroenterology Week (UEGW) 2020 Meeting last month.
  • Initiating assessment of the application begins the formal evaluation process by the EMAs Committee for Human Medicinal Products (CHMP).
  • Further, it is possible that the parties may make a strategic decision to discontinue development of filgotinib for the treatment of ulcerative colitis or other indications, and as a result, filgotinib may never be successfully commercialized for the treatment of ulcerative colitis or other indications.

Ulcerative Colitis Market Report 2020: Pipeline, Epidemiology, Competitive Analysis, Drug Sales and Shares through 2016-2024

Retrieved on: 
Tuesday, May 12, 2020
Medical specialties, Medicine, Clinical medicine, Autoimmune diseases, Monoclonal antibodies, Gastroenterology, RTT, Colitis, Ulcerative colitis, Management of ulcerative colitis, Vedolizumab, Visilizumab

DUBLIN, May 12, 2020 /PRNewswire/ -- The "Global Ulcerative Colitis Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 12, 2020 /PRNewswire/ -- The "Global Ulcerative Colitis Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This research report provides comprehensive insights into the Ulcerative Colitis pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • The research analyzes and forecasts the Ulcerative Colitis market size and drug sales.
  • Ulcerative Colitis pipeline: Find out drugs in clinical trials for the treatment of Ulcerative Colitis by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Ulcerative Colitis drugs: Identify key drugs marketed and prescribed for Ulcerative Colitis in the US, including trade name, molecule name, and company
    Ulcerative Colitis market valuations: Find out the market size for Ulcerative Colitis drugs in 2019 by countries.

Ulcerative Colitis Industry Review and Outlook 2016-2024 - ResearchAndMarkets.com

Retrieved on: 
Monday, May 11, 2020
Health, Pharmaceutical, Medical specialties, Medicine, Clinical medicine, Autoimmune diseases, Colitis, Monoclonal antibodies, RTT, Gastroenterology, Ulcerative colitis, Management of ulcerative colitis, Vedolizumab, Visilizumab

The "Global Ulcerative Colitis Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Ulcerative Colitis Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This research report provides comprehensive insights into the Ulcerative Colitis pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • The research analyzes and forecasts the Ulcerative Colitis market size and drug sales.
  • Ulcerative Colitis pipeline: Find out drugs in clinical trials for the treatment of Ulcerative Colitis by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Ulcerative Colitis drugs: Identify key drugs marketed and prescribed for Ulcerative Colitis in the US, including trade name, molecule name, and company
    Ulcerative Colitis market valuations: Find out the market size for Ulcerative Colitis drugs in 2019 by countries.

2020 Ulcerative Colitis (UC) Pipeline Landscape Overview - ResearchAndMarkets.com

Retrieved on: 
Monday, April 20, 2020
Health, General Health, Medical specialties, Medicine, Clinical medicine, Autoimmune diseases, Diarrhea, Colitis, Monoclonal antibodies, Gastroenterology, Ulcerative colitis, Management of ulcerative colitis

Ulcerative Colitis (UC) Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Ulcerative Colitis (UC) market.

Key Points: 
  • Ulcerative Colitis (UC) Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Ulcerative Colitis (UC) market.
  • A detailed picture of the Ulcerative Colitis (UC) pipeline landscape is provided, which includes the disease overview and Ulcerative Colitis (UC) treatment guidelines.
  • The assessment part of the report embraces in-depth Ulcerative Colitis (UC) commercial assessment and clinical assessment of the Ulcerative Colitis (UC) pipeline products from the pre-clinical developmental phase to the marketed phase.
  • How many Ulcerative Colitis (UC) emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Ulcerative Colitis (UC)?

InDex Pharmaceuticals Publishes Mechanism of Action Data for Cobitolimod in Scientific Journal

Retrieved on: 
Tuesday, February 25, 2020
Medical specialties, Medicine, Clinical medicine, Diarrhea, Autoimmune diseases, Monoclonal antibodies, RTT, Ulcerative colitis, Colitis, Management of ulcerative colitis

STOCKHOLM, Feb. 25, 2020 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced the publication of scientific data on the mechanism of action of cobitolimod, the company's lead drug candidate in development for the treatment of moderate to severe ulcerative colitis.

Key Points: 
  • STOCKHOLM, Feb. 25, 2020 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced the publication of scientific data on the mechanism of action of cobitolimod, the company's lead drug candidate in development for the treatment of moderate to severe ulcerative colitis.
  • "Cobitolimod is an innovative drug candidate with a unique mechanism of action for the treatment of ulcerative colitis.
  • That JCC also chooses to highlight the data in their podcast, shows that there is a great interest from the scientific community," said Peter Zerhouni, CEO of InDex Pharmaceuticals.
  • "This supporting mechanistic data fits very nicely with the successful clinical results obtained with cobitolimod in our phase IIb study CONDUCT."

InDex Pharmaceuticals Publishes Mechanism of Action Data for Cobitolimod in Scientific Journal

Retrieved on: 
Tuesday, February 25, 2020
Medical specialties, Medicine, Clinical medicine, Diarrhea, Autoimmune diseases, Monoclonal antibodies, RTT, Ulcerative colitis, Colitis, Management of ulcerative colitis

STOCKHOLM, Feb. 25, 2020 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced the publication of scientific data on the mechanism of action of cobitolimod, the company's lead drug candidate in development for the treatment of moderate to severe ulcerative colitis.

Key Points: 
  • STOCKHOLM, Feb. 25, 2020 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced the publication of scientific data on the mechanism of action of cobitolimod, the company's lead drug candidate in development for the treatment of moderate to severe ulcerative colitis.
  • "Cobitolimod is an innovative drug candidate with a unique mechanism of action for the treatment of ulcerative colitis.
  • That JCC also chooses to highlight the data in their podcast, shows that there is a great interest from the scientific community," said Peter Zerhouni, CEO of InDex Pharmaceuticals.
  • "This supporting mechanistic data fits very nicely with the successful clinical results obtained with cobitolimod in our phase IIb study CONDUCT."

Innovation Pharmaceuticals Phase 1 Trial of Brilacidin for Ulcerative Colitis Meets Primary Endpoints; Positive Topline Results of Oral Brilacidin

Retrieved on: 
Thursday, February 13, 2020
Medical specialties, Medicine, Clinical medicine, Autoimmune diseases, Brilacidin, Proctitis, Tablet, Management of ulcerative colitis

Study results show that Brilacidin delayed-release tablets were well tolerated across all treatment cohorts with no serious adverse events reported.

Key Points: 
  • Study results show that Brilacidin delayed-release tablets were well tolerated across all treatment cohorts with no serious adverse events reported.
  • Serial blood samples were collected through 24 hours post-dose to assess absorption of oral Brilacidin from the colon.
  • The Company plans to advance Brilacidin oral rinse into Phase 3 development, subject to available financial resources.
  • Positive results were also observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS).

United States Ulcerative Colitis Market and Competitive Landscape Report 2019-2024 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 1, 2019
Health, Pharmaceutical, Medical specialties, Medicine, Clinical medicine, Autoimmune diseases, Colitis, RTT, Gastroenterology, Monoclonal antibodies, Ulcerative colitis, Management of ulcerative colitis, Ulcer, Vedolizumab

The "US Ulcerative Colitis Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Ulcerative Colitis Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.
  • United States Ulcerative Colitis Market and Competitive Landscape Highlights - 2019, provides comprehensive insights into Ulcerative Colitis pipeline products, Ulcerative Colitis epidemiology, Ulcerative Colitis market valuations and forecast, Ulcerative Colitis drugs sales and competitive landscape in the US.
  • Ulcerative Colitis pipeline: Find out the products in clinical trials for the treatment of Ulcerative Colitis by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Ulcerative Colitis drugs: Identify key products marketed and prescribed for Ulcerative Colitis in the US, including trade name, molecule name, and company
    Ulcerative Colitis market valuations: Find out the market size for Ulcerative Colitis drugs in 2018 in the US.
  • Find out how the market advanced from 2014 and forecast to 2024
    Ulcerative Colitis drugs market share: Find out the market shares for key Ulcerative Colitis drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Ulcerative Colitis products